| SKŘIČKOVÁ, Jana, Bohdan KADLEC, Ondřej VENCLÍČEK, Lenka JAKUBÍKOVÁ, Tereza JANÁSKOVÁ, Vítězslav KOLEK, Ivona GRYGÁRKOVÁ, Helena ČOUPKOVÁ, Jiří CHALUPA, Jiří BARTOŠ, Pavel REITERER a Milada ZEMANOVÁ. Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient. Online. In 15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia. 2013. ISSN 1556-0864. [citováno 2024-04-24] |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1136258,
author = {Skřičková, Jana and Kadlec, Bohdan and Venclíček, Ondřej and Jakubíková, Lenka and Janásková, Tereza and Kolek, Vítězslav and Grygárková, Ivona and Čoupková, Helena and Chalupa, Jiří and Bartoš, Jiří and Reiterer, Pavel and Zemanová, Milada},
booktitle = {15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia},
keywords = {first-line treatment; NSCLC},
language = {eng},
title = {Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient},
year = {2013}
}
TY - CONF
ID - 1136258
AU - Skřičková, Jana - Kadlec, Bohdan - Venclíček, Ondřej - Jakubíková, Lenka - Janásková, Tereza - Kolek, Vítězslav - Grygárková, Ivona - Čoupková, Helena - Chalupa, Jiří - Bartoš, Jiří - Reiterer, Pavel - Zemanová, Milada
PY - 2013
TI - Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient
KW - first-line treatment
KW - NSCLC
N2 - In this group of 396 unselected patients with advanced NSCLC was the treatment with full NVBO and-CBDCA in first line more convenient and well tolerated with evidence of high antitumour activity. This combination was active in all groups patients according histology (mOS was 9,92 and mPFS was 7,4 months). Statistically significant better were the results in patients with PS 0+1.
ER -
SKŘIČKOVÁ, Jana, Bohdan KADLEC, Ondřej VENCLÍČEK, Lenka JAKUBÍKOVÁ, Tereza JANÁSKOVÁ, Vítězslav KOLEK, Ivona GRYGÁRKOVÁ, Helena ČOUPKOVÁ, Jiří CHALUPA, Jiří BARTOŠ, Pavel REITERER a Milada ZEMANOVÁ. Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient. Online. In \textit{15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia}. 2013. ISSN~1556-0864. [citováno 2024-04-24]
|
